SAT-3247

Satellos Bioscience, Inc. · Phase 2 active Small molecule

At a glance

Generic name	SAT-3247
Also known as	SAT3247, AAK1 inhibitor
Sponsor	Satellos Bioscience, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients (PHASE2)
A Long-term Follow-up Study for Participants That Completed the SAT-3247-CL-101 Study (PHASE2)
First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SAT-3247 CI brief — competitive landscape report
SAT-3247 updates RSS · CI watch RSS
Satellos Bioscience, Inc. portfolio CI